Discovering first-in-class drug candidates to restore intestinal barrier function in IBD.
Discovering first-in-class drug candidates for dual treatment of fibrosis and inflammation in IBD.
Developing first-in-class LRH-1 agonists to restore immune balance and induce intestinal mucosa healing.
Microbiome therapy for patients who have underlying microbiome disruption associated with IBD
PPARγ partial agonist as a potential therapy for fibrosis in Crohn’s disease
Driving precision medicine by modulating the TREM-1 pathway in a specific patient population to achieve a balanced innate immune response in IBD
Live biotherapeutic used in conjunction with corticosteroids to enhance mucosal healing and prevent relapse in IBD patients
A prodrug activated in the gut by bacterial enzymes releases the active PDE4 inhibitor for the treatment of moderate-to-severe Ulcerative Colitis
Orally administered single bacterial microorganism for treating IBD
Wearable device for monitoring levels of IBD-associated biomarkers in sweat.
Developing colon sensing pills designed for targeted drug delivery to the GI tract to improve patients’ outcomes.
LRH-1 agonist to mitigate excessive inflammation and foster the healing and regeneration of tissue damaged by IBD.
Your Internet Explorer is outdated. For optimal security settings and a better experience on our site, try switching to one of these options:
Google Chrome
Firefox
Safari (macOS 10.8+ only)
